29 EMMONS DRIVE, PRINCETON, NJ
Material Contracts, Other Events
FDA Grants Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results
News
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the Treatment of Behçet’s Disease
News, Material Contracts
Annual Report to Security Holders
End of Material Contract
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload